Abbott faces criminal investigation over baby formula, says report

The Michigan plant came to national attention in 2022 after FDA, while fielding reports of infants sickened by formula produced there, found strikingly unsanitary co

Abbott
Though FDA inspectors who swabbed the area near production lines at the plant found samples of the bacteria
NYT
2 min read Last Updated : Jan 22 2023 | 10:29 PM IST
The US Department of Justice has opened an investigation into operations at the Abbott Nutrition infant formula plant in Michigan that shut down over sanitation problems early last year, causing a lengthy and widespread infant formula shortage.

The company confirmed the investigation in an email but offered no further details, other than that it was “cooperating fully,” according to an Abbott spokesman.

The Michigan plant came to national attention in 2022 after the Food and Drug Administration (FDA), while fielding reports of infants sickened by formula produced there, found strikingly unsanitary conditions, including puddles of water on the floor near production lines. 

In February, the agency urged the company to recall Similac and other widely used infant formulas, FDA records show. Abbott voluntarily ceased production at the plant for several months. 

Baby formula was already scarce because of pandemic-related supply chain issues, but the Abbott recall made the situation much worse. Parents reported hunting for hours to find formula needed to feed their infants. By May, President Biden was deploying military planes to airlift infant formula into the US.

The investigation was previously reported by The Wall Street Journal. The Department of Justice declined to comment.

Four infants in three states — Minnesota, Ohio and Texas — fell ill with the dangerous Cronobactor sakazakii bacteria starting in September 2021, and two of them died. 

Though FDA inspectors who swabbed the area near production lines at the plant found samples of the bacteria, its records show, no strain associated with an infant was directly linked to the facility.

Lawmakers held hearings about the crisis, discussing the FDA’s fumbling of a whistle-blower complaint from an Abbott insider who asserted that the plant did not destroy a batch of formula found to include micro-organisms because “senior management was under significant pressure to meet its ‘numbers.’

©2023 The New York Times News Service

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :US FDAhealthcare

Next Story